Global Digital Medicines Market

Digital Medicines Comprehensive Study by Type (Mobile Health, EMR/EHR, Telehealth, Wireless Health), Application (Diabetes, Mental Health, Heart Disease, Smoking, Drug Non-adherence, Obesity, COPD, Asthma), Components (Wearables, Apps, Sensors, Other IoT devices), End User (Personal, Hospitals, Laboratory, Other) Players and Region - Global Market Outlook to 2025

Digital Medicines Market by XX Submarkets | Forecast Years 2021-2026  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Digital Medicines Market Overview:
Digital medicine refers to use of evidence based technology and product that rely on health information to diagnose, prevent, monitoring or treat disease and disease conditions. Technologies such as telemedicine are redefining how doctors and patients interact. Digital medicine technology is more privileged then current medical practice since it is more precise and effective technology. Due to the growing number of chronic disease the market of digital medicine is growing while some of the factor like high cost associated with it is hampering the growth of market. Some of the key players profiled in the study are 2Morrow (United States), Livongo Health (United States), WellDoc (United States), Wellthy Therapeutics (India), Ayogo Health (Canada), Proteus Digital Health (United States), Omada Health (United States), Noom (United States), Pear Therapeutics (United States) and Propeller Health (United States).

On the basis of geography, the market of Digital Medicines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Components, the sub-segment i.e. Wearables will boost the Digital Medicines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Personal will boost the Digital Medicines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing usage of smartphones in healthcare
  • Benefits associated with the digital medicines
  • Growing number of population associated with the chronic diseases

Market Trend
  • Rapid growth in development of medical software applications

Restraints
  • High cost associated with it
  • Trust issue associated with digital medicine

Opportunities
  • Rising expenditure in digital healthcare
  • Emerging market in many regions

Challenges
  • Unaware about this in many regions



The ingestible sensor component associated with digital medicines was originally approved in 2012 by the U.S. Food and Drug Administration (FDA) through the Center for Devices and Radiological Health via a de novo pathway for novel, low-risk medical devices. This approval has been accompanied by FDA 510(k) clearances. The ingestible sensor is CE marked in Europe.
The market is consolidated, with a few leading players. Key companies are indulging in various strategies to expand. Those include product launch, and mergers and acquisitions. The players are working hard to expand their reach and increase their consumer base all over the globe.

Target Audience:
Digital Medicines Developers, Academic research institute, Hospitals and Clinics, Pharmaceuticals companies, Biotechnology companies, Contract research organization and Market research and consulting firms

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Digital Medicines market on the basis of product [Mobile Health, EMR/EHR, Telehealth and Wireless Health] , application [Diabetes, Mental Health, Heart Disease, Smoking, Drug Non-adherence, Obesity, COPD and Asthma], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Digital Medicines market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Digital Medicines industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Akili Interactive Labs, Voluntis and AliveCor.
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Digital Medicines market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.

Report Objectives / Segmentation Covered

By Type
  • Mobile Health
  • EMR/EHR
  • Telehealth
  • Wireless Health
By Application
  • Diabetes
  • Mental Health
  • Heart Disease
  • Smoking
  • Drug Non-adherence
  • Obesity
  • COPD
  • Asthma
By Components
  • Wearables
  • Apps
  • Sensors
  • Other IoT devices

By End User
  • Personal
  • Hospitals
  • Laboratory
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing usage of smartphones in healthcare
      • 3.2.2. Benefits associated with the digital medicines
      • 3.2.3. Growing number of population associated with the chronic diseases
    • 3.3. Market Challenges
      • 3.3.1. Unaware about this in many regions
    • 3.4. Market Trends
      • 3.4.1. Rapid growth in development of medical software applications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Digital Medicines, by Type, Application, Components, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Digital Medicines (Value)
      • 5.2.1. Global Digital Medicines by: Type (Value)
        • 5.2.1.1. Mobile Health
        • 5.2.1.2. EMR/EHR
        • 5.2.1.3. Telehealth
        • 5.2.1.4. Wireless Health
      • 5.2.2. Global Digital Medicines by: Application (Value)
        • 5.2.2.1. Diabetes
        • 5.2.2.2. Mental Health
        • 5.2.2.3. Heart Disease
        • 5.2.2.4. Smoking
        • 5.2.2.5. Drug Non-adherence
        • 5.2.2.6. Obesity
        • 5.2.2.7. COPD
        • 5.2.2.8. Asthma
      • 5.2.3. Global Digital Medicines by: Components (Value)
        • 5.2.3.1. Wearables
        • 5.2.3.2. Apps
        • 5.2.3.3. Sensors
        • 5.2.3.4. Other IoT devices
      • 5.2.4. Global Digital Medicines by: End User (Value)
        • 5.2.4.1. Personal
        • 5.2.4.2. Hospitals
        • 5.2.4.3. Laboratory
        • 5.2.4.4. Other
      • 5.2.5. Global Digital Medicines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Digital Medicines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. 2Morrow (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Livongo Health (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. WellDoc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Wellthy Therapeutics (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ayogo Health (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Proteus Digital Health (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Omada Health (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Noom (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pear Therapeutics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Propeller Health (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Digital Medicines Sale, by Type, Application, Components, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Digital Medicines (Value)
      • 7.2.1. Global Digital Medicines by: Type (Value)
        • 7.2.1.1. Mobile Health
        • 7.2.1.2. EMR/EHR
        • 7.2.1.3. Telehealth
        • 7.2.1.4. Wireless Health
      • 7.2.2. Global Digital Medicines by: Application (Value)
        • 7.2.2.1. Diabetes
        • 7.2.2.2. Mental Health
        • 7.2.2.3. Heart Disease
        • 7.2.2.4. Smoking
        • 7.2.2.5. Drug Non-adherence
        • 7.2.2.6. Obesity
        • 7.2.2.7. COPD
        • 7.2.2.8. Asthma
      • 7.2.3. Global Digital Medicines by: Components (Value)
        • 7.2.3.1. Wearables
        • 7.2.3.2. Apps
        • 7.2.3.3. Sensors
        • 7.2.3.4. Other IoT devices
      • 7.2.4. Global Digital Medicines by: End User (Value)
        • 7.2.4.1. Personal
        • 7.2.4.2. Hospitals
        • 7.2.4.3. Laboratory
        • 7.2.4.4. Other
      • 7.2.5. Global Digital Medicines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Digital Medicines: by Type(USD Million)
  • Table 2. Digital Medicines Mobile Health , by Region USD Million (2014-2019)
  • Table 3. Digital Medicines EMR/EHR , by Region USD Million (2014-2019)
  • Table 4. Digital Medicines Telehealth , by Region USD Million (2014-2019)
  • Table 5. Digital Medicines Wireless Health , by Region USD Million (2014-2019)
  • Table 6. Digital Medicines: by Application(USD Million)
  • Table 7. Digital Medicines Diabetes , by Region USD Million (2014-2019)
  • Table 8. Digital Medicines Mental Health , by Region USD Million (2014-2019)
  • Table 9. Digital Medicines Heart Disease , by Region USD Million (2014-2019)
  • Table 10. Digital Medicines Smoking , by Region USD Million (2014-2019)
  • Table 11. Digital Medicines Drug Non-adherence , by Region USD Million (2014-2019)
  • Table 12. Digital Medicines Obesity , by Region USD Million (2014-2019)
  • Table 13. Digital Medicines COPD , by Region USD Million (2014-2019)
  • Table 14. Digital Medicines Asthma , by Region USD Million (2014-2019)
  • Table 15. Digital Medicines: by Components(USD Million)
  • Table 16. Digital Medicines Wearables , by Region USD Million (2014-2019)
  • Table 17. Digital Medicines Apps , by Region USD Million (2014-2019)
  • Table 18. Digital Medicines Sensors , by Region USD Million (2014-2019)
  • Table 19. Digital Medicines Other IoT devices , by Region USD Million (2014-2019)
  • Table 20. Digital Medicines: by End User(USD Million)
  • Table 21. Digital Medicines Personal , by Region USD Million (2014-2019)
  • Table 22. Digital Medicines Hospitals , by Region USD Million (2014-2019)
  • Table 23. Digital Medicines Laboratory , by Region USD Million (2014-2019)
  • Table 24. Digital Medicines Other , by Region USD Million (2014-2019)
  • Table 25. South America Digital Medicines, by Country USD Million (2014-2019)
  • Table 26. South America Digital Medicines, by Type USD Million (2014-2019)
  • Table 27. South America Digital Medicines, by Application USD Million (2014-2019)
  • Table 28. South America Digital Medicines, by Components USD Million (2014-2019)
  • Table 29. South America Digital Medicines, by End User USD Million (2014-2019)
  • Table 30. Brazil Digital Medicines, by Type USD Million (2014-2019)
  • Table 31. Brazil Digital Medicines, by Application USD Million (2014-2019)
  • Table 32. Brazil Digital Medicines, by Components USD Million (2014-2019)
  • Table 33. Brazil Digital Medicines, by End User USD Million (2014-2019)
  • Table 34. Argentina Digital Medicines, by Type USD Million (2014-2019)
  • Table 35. Argentina Digital Medicines, by Application USD Million (2014-2019)
  • Table 36. Argentina Digital Medicines, by Components USD Million (2014-2019)
  • Table 37. Argentina Digital Medicines, by End User USD Million (2014-2019)
  • Table 38. Rest of South America Digital Medicines, by Type USD Million (2014-2019)
  • Table 39. Rest of South America Digital Medicines, by Application USD Million (2014-2019)
  • Table 40. Rest of South America Digital Medicines, by Components USD Million (2014-2019)
  • Table 41. Rest of South America Digital Medicines, by End User USD Million (2014-2019)
  • Table 42. Asia Pacific Digital Medicines, by Country USD Million (2014-2019)
  • Table 43. Asia Pacific Digital Medicines, by Type USD Million (2014-2019)
  • Table 44. Asia Pacific Digital Medicines, by Application USD Million (2014-2019)
  • Table 45. Asia Pacific Digital Medicines, by Components USD Million (2014-2019)
  • Table 46. Asia Pacific Digital Medicines, by End User USD Million (2014-2019)
  • Table 47. China Digital Medicines, by Type USD Million (2014-2019)
  • Table 48. China Digital Medicines, by Application USD Million (2014-2019)
  • Table 49. China Digital Medicines, by Components USD Million (2014-2019)
  • Table 50. China Digital Medicines, by End User USD Million (2014-2019)
  • Table 51. Japan Digital Medicines, by Type USD Million (2014-2019)
  • Table 52. Japan Digital Medicines, by Application USD Million (2014-2019)
  • Table 53. Japan Digital Medicines, by Components USD Million (2014-2019)
  • Table 54. Japan Digital Medicines, by End User USD Million (2014-2019)
  • Table 55. India Digital Medicines, by Type USD Million (2014-2019)
  • Table 56. India Digital Medicines, by Application USD Million (2014-2019)
  • Table 57. India Digital Medicines, by Components USD Million (2014-2019)
  • Table 58. India Digital Medicines, by End User USD Million (2014-2019)
  • Table 59. South Korea Digital Medicines, by Type USD Million (2014-2019)
  • Table 60. South Korea Digital Medicines, by Application USD Million (2014-2019)
  • Table 61. South Korea Digital Medicines, by Components USD Million (2014-2019)
  • Table 62. South Korea Digital Medicines, by End User USD Million (2014-2019)
  • Table 63. Taiwan Digital Medicines, by Type USD Million (2014-2019)
  • Table 64. Taiwan Digital Medicines, by Application USD Million (2014-2019)
  • Table 65. Taiwan Digital Medicines, by Components USD Million (2014-2019)
  • Table 66. Taiwan Digital Medicines, by End User USD Million (2014-2019)
  • Table 67. Australia Digital Medicines, by Type USD Million (2014-2019)
  • Table 68. Australia Digital Medicines, by Application USD Million (2014-2019)
  • Table 69. Australia Digital Medicines, by Components USD Million (2014-2019)
  • Table 70. Australia Digital Medicines, by End User USD Million (2014-2019)
  • Table 71. Rest of Asia-Pacific Digital Medicines, by Type USD Million (2014-2019)
  • Table 72. Rest of Asia-Pacific Digital Medicines, by Application USD Million (2014-2019)
  • Table 73. Rest of Asia-Pacific Digital Medicines, by Components USD Million (2014-2019)
  • Table 74. Rest of Asia-Pacific Digital Medicines, by End User USD Million (2014-2019)
  • Table 75. Europe Digital Medicines, by Country USD Million (2014-2019)
  • Table 76. Europe Digital Medicines, by Type USD Million (2014-2019)
  • Table 77. Europe Digital Medicines, by Application USD Million (2014-2019)
  • Table 78. Europe Digital Medicines, by Components USD Million (2014-2019)
  • Table 79. Europe Digital Medicines, by End User USD Million (2014-2019)
  • Table 80. Germany Digital Medicines, by Type USD Million (2014-2019)
  • Table 81. Germany Digital Medicines, by Application USD Million (2014-2019)
  • Table 82. Germany Digital Medicines, by Components USD Million (2014-2019)
  • Table 83. Germany Digital Medicines, by End User USD Million (2014-2019)
  • Table 84. France Digital Medicines, by Type USD Million (2014-2019)
  • Table 85. France Digital Medicines, by Application USD Million (2014-2019)
  • Table 86. France Digital Medicines, by Components USD Million (2014-2019)
  • Table 87. France Digital Medicines, by End User USD Million (2014-2019)
  • Table 88. Italy Digital Medicines, by Type USD Million (2014-2019)
  • Table 89. Italy Digital Medicines, by Application USD Million (2014-2019)
  • Table 90. Italy Digital Medicines, by Components USD Million (2014-2019)
  • Table 91. Italy Digital Medicines, by End User USD Million (2014-2019)
  • Table 92. United Kingdom Digital Medicines, by Type USD Million (2014-2019)
  • Table 93. United Kingdom Digital Medicines, by Application USD Million (2014-2019)
  • Table 94. United Kingdom Digital Medicines, by Components USD Million (2014-2019)
  • Table 95. United Kingdom Digital Medicines, by End User USD Million (2014-2019)
  • Table 96. Netherlands Digital Medicines, by Type USD Million (2014-2019)
  • Table 97. Netherlands Digital Medicines, by Application USD Million (2014-2019)
  • Table 98. Netherlands Digital Medicines, by Components USD Million (2014-2019)
  • Table 99. Netherlands Digital Medicines, by End User USD Million (2014-2019)
  • Table 100. Rest of Europe Digital Medicines, by Type USD Million (2014-2019)
  • Table 101. Rest of Europe Digital Medicines, by Application USD Million (2014-2019)
  • Table 102. Rest of Europe Digital Medicines, by Components USD Million (2014-2019)
  • Table 103. Rest of Europe Digital Medicines, by End User USD Million (2014-2019)
  • Table 104. MEA Digital Medicines, by Country USD Million (2014-2019)
  • Table 105. MEA Digital Medicines, by Type USD Million (2014-2019)
  • Table 106. MEA Digital Medicines, by Application USD Million (2014-2019)
  • Table 107. MEA Digital Medicines, by Components USD Million (2014-2019)
  • Table 108. MEA Digital Medicines, by End User USD Million (2014-2019)
  • Table 109. Middle East Digital Medicines, by Type USD Million (2014-2019)
  • Table 110. Middle East Digital Medicines, by Application USD Million (2014-2019)
  • Table 111. Middle East Digital Medicines, by Components USD Million (2014-2019)
  • Table 112. Middle East Digital Medicines, by End User USD Million (2014-2019)
  • Table 113. Africa Digital Medicines, by Type USD Million (2014-2019)
  • Table 114. Africa Digital Medicines, by Application USD Million (2014-2019)
  • Table 115. Africa Digital Medicines, by Components USD Million (2014-2019)
  • Table 116. Africa Digital Medicines, by End User USD Million (2014-2019)
  • Table 117. North America Digital Medicines, by Country USD Million (2014-2019)
  • Table 118. North America Digital Medicines, by Type USD Million (2014-2019)
  • Table 119. North America Digital Medicines, by Application USD Million (2014-2019)
  • Table 120. North America Digital Medicines, by Components USD Million (2014-2019)
  • Table 121. North America Digital Medicines, by End User USD Million (2014-2019)
  • Table 122. United States Digital Medicines, by Type USD Million (2014-2019)
  • Table 123. United States Digital Medicines, by Application USD Million (2014-2019)
  • Table 124. United States Digital Medicines, by Components USD Million (2014-2019)
  • Table 125. United States Digital Medicines, by End User USD Million (2014-2019)
  • Table 126. Canada Digital Medicines, by Type USD Million (2014-2019)
  • Table 127. Canada Digital Medicines, by Application USD Million (2014-2019)
  • Table 128. Canada Digital Medicines, by Components USD Million (2014-2019)
  • Table 129. Canada Digital Medicines, by End User USD Million (2014-2019)
  • Table 130. Mexico Digital Medicines, by Type USD Million (2014-2019)
  • Table 131. Mexico Digital Medicines, by Application USD Million (2014-2019)
  • Table 132. Mexico Digital Medicines, by Components USD Million (2014-2019)
  • Table 133. Mexico Digital Medicines, by End User USD Million (2014-2019)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Digital Medicines: by Type(USD Million)
  • Table 145. Digital Medicines Mobile Health , by Region USD Million (2020-2025)
  • Table 146. Digital Medicines EMR/EHR , by Region USD Million (2020-2025)
  • Table 147. Digital Medicines Telehealth , by Region USD Million (2020-2025)
  • Table 148. Digital Medicines Wireless Health , by Region USD Million (2020-2025)
  • Table 149. Digital Medicines: by Application(USD Million)
  • Table 150. Digital Medicines Diabetes , by Region USD Million (2020-2025)
  • Table 151. Digital Medicines Mental Health , by Region USD Million (2020-2025)
  • Table 152. Digital Medicines Heart Disease , by Region USD Million (2020-2025)
  • Table 153. Digital Medicines Smoking , by Region USD Million (2020-2025)
  • Table 154. Digital Medicines Drug Non-adherence , by Region USD Million (2020-2025)
  • Table 155. Digital Medicines Obesity , by Region USD Million (2020-2025)
  • Table 156. Digital Medicines COPD , by Region USD Million (2020-2025)
  • Table 157. Digital Medicines Asthma , by Region USD Million (2020-2025)
  • Table 158. Digital Medicines: by Components(USD Million)
  • Table 159. Digital Medicines Wearables , by Region USD Million (2020-2025)
  • Table 160. Digital Medicines Apps , by Region USD Million (2020-2025)
  • Table 161. Digital Medicines Sensors , by Region USD Million (2020-2025)
  • Table 162. Digital Medicines Other IoT devices , by Region USD Million (2020-2025)
  • Table 163. Digital Medicines: by End User(USD Million)
  • Table 164. Digital Medicines Personal , by Region USD Million (2020-2025)
  • Table 165. Digital Medicines Hospitals , by Region USD Million (2020-2025)
  • Table 166. Digital Medicines Laboratory , by Region USD Million (2020-2025)
  • Table 167. Digital Medicines Other , by Region USD Million (2020-2025)
  • Table 168. South America Digital Medicines, by Country USD Million (2020-2025)
  • Table 169. South America Digital Medicines, by Type USD Million (2020-2025)
  • Table 170. South America Digital Medicines, by Application USD Million (2020-2025)
  • Table 171. South America Digital Medicines, by Components USD Million (2020-2025)
  • Table 172. South America Digital Medicines, by End User USD Million (2020-2025)
  • Table 173. Brazil Digital Medicines, by Type USD Million (2020-2025)
  • Table 174. Brazil Digital Medicines, by Application USD Million (2020-2025)
  • Table 175. Brazil Digital Medicines, by Components USD Million (2020-2025)
  • Table 176. Brazil Digital Medicines, by End User USD Million (2020-2025)
  • Table 177. Argentina Digital Medicines, by Type USD Million (2020-2025)
  • Table 178. Argentina Digital Medicines, by Application USD Million (2020-2025)
  • Table 179. Argentina Digital Medicines, by Components USD Million (2020-2025)
  • Table 180. Argentina Digital Medicines, by End User USD Million (2020-2025)
  • Table 181. Rest of South America Digital Medicines, by Type USD Million (2020-2025)
  • Table 182. Rest of South America Digital Medicines, by Application USD Million (2020-2025)
  • Table 183. Rest of South America Digital Medicines, by Components USD Million (2020-2025)
  • Table 184. Rest of South America Digital Medicines, by End User USD Million (2020-2025)
  • Table 185. Asia Pacific Digital Medicines, by Country USD Million (2020-2025)
  • Table 186. Asia Pacific Digital Medicines, by Type USD Million (2020-2025)
  • Table 187. Asia Pacific Digital Medicines, by Application USD Million (2020-2025)
  • Table 188. Asia Pacific Digital Medicines, by Components USD Million (2020-2025)
  • Table 189. Asia Pacific Digital Medicines, by End User USD Million (2020-2025)
  • Table 190. China Digital Medicines, by Type USD Million (2020-2025)
  • Table 191. China Digital Medicines, by Application USD Million (2020-2025)
  • Table 192. China Digital Medicines, by Components USD Million (2020-2025)
  • Table 193. China Digital Medicines, by End User USD Million (2020-2025)
  • Table 194. Japan Digital Medicines, by Type USD Million (2020-2025)
  • Table 195. Japan Digital Medicines, by Application USD Million (2020-2025)
  • Table 196. Japan Digital Medicines, by Components USD Million (2020-2025)
  • Table 197. Japan Digital Medicines, by End User USD Million (2020-2025)
  • Table 198. India Digital Medicines, by Type USD Million (2020-2025)
  • Table 199. India Digital Medicines, by Application USD Million (2020-2025)
  • Table 200. India Digital Medicines, by Components USD Million (2020-2025)
  • Table 201. India Digital Medicines, by End User USD Million (2020-2025)
  • Table 202. South Korea Digital Medicines, by Type USD Million (2020-2025)
  • Table 203. South Korea Digital Medicines, by Application USD Million (2020-2025)
  • Table 204. South Korea Digital Medicines, by Components USD Million (2020-2025)
  • Table 205. South Korea Digital Medicines, by End User USD Million (2020-2025)
  • Table 206. Taiwan Digital Medicines, by Type USD Million (2020-2025)
  • Table 207. Taiwan Digital Medicines, by Application USD Million (2020-2025)
  • Table 208. Taiwan Digital Medicines, by Components USD Million (2020-2025)
  • Table 209. Taiwan Digital Medicines, by End User USD Million (2020-2025)
  • Table 210. Australia Digital Medicines, by Type USD Million (2020-2025)
  • Table 211. Australia Digital Medicines, by Application USD Million (2020-2025)
  • Table 212. Australia Digital Medicines, by Components USD Million (2020-2025)
  • Table 213. Australia Digital Medicines, by End User USD Million (2020-2025)
  • Table 214. Rest of Asia-Pacific Digital Medicines, by Type USD Million (2020-2025)
  • Table 215. Rest of Asia-Pacific Digital Medicines, by Application USD Million (2020-2025)
  • Table 216. Rest of Asia-Pacific Digital Medicines, by Components USD Million (2020-2025)
  • Table 217. Rest of Asia-Pacific Digital Medicines, by End User USD Million (2020-2025)
  • Table 218. Europe Digital Medicines, by Country USD Million (2020-2025)
  • Table 219. Europe Digital Medicines, by Type USD Million (2020-2025)
  • Table 220. Europe Digital Medicines, by Application USD Million (2020-2025)
  • Table 221. Europe Digital Medicines, by Components USD Million (2020-2025)
  • Table 222. Europe Digital Medicines, by End User USD Million (2020-2025)
  • Table 223. Germany Digital Medicines, by Type USD Million (2020-2025)
  • Table 224. Germany Digital Medicines, by Application USD Million (2020-2025)
  • Table 225. Germany Digital Medicines, by Components USD Million (2020-2025)
  • Table 226. Germany Digital Medicines, by End User USD Million (2020-2025)
  • Table 227. France Digital Medicines, by Type USD Million (2020-2025)
  • Table 228. France Digital Medicines, by Application USD Million (2020-2025)
  • Table 229. France Digital Medicines, by Components USD Million (2020-2025)
  • Table 230. France Digital Medicines, by End User USD Million (2020-2025)
  • Table 231. Italy Digital Medicines, by Type USD Million (2020-2025)
  • Table 232. Italy Digital Medicines, by Application USD Million (2020-2025)
  • Table 233. Italy Digital Medicines, by Components USD Million (2020-2025)
  • Table 234. Italy Digital Medicines, by End User USD Million (2020-2025)
  • Table 235. United Kingdom Digital Medicines, by Type USD Million (2020-2025)
  • Table 236. United Kingdom Digital Medicines, by Application USD Million (2020-2025)
  • Table 237. United Kingdom Digital Medicines, by Components USD Million (2020-2025)
  • Table 238. United Kingdom Digital Medicines, by End User USD Million (2020-2025)
  • Table 239. Netherlands Digital Medicines, by Type USD Million (2020-2025)
  • Table 240. Netherlands Digital Medicines, by Application USD Million (2020-2025)
  • Table 241. Netherlands Digital Medicines, by Components USD Million (2020-2025)
  • Table 242. Netherlands Digital Medicines, by End User USD Million (2020-2025)
  • Table 243. Rest of Europe Digital Medicines, by Type USD Million (2020-2025)
  • Table 244. Rest of Europe Digital Medicines, by Application USD Million (2020-2025)
  • Table 245. Rest of Europe Digital Medicines, by Components USD Million (2020-2025)
  • Table 246. Rest of Europe Digital Medicines, by End User USD Million (2020-2025)
  • Table 247. MEA Digital Medicines, by Country USD Million (2020-2025)
  • Table 248. MEA Digital Medicines, by Type USD Million (2020-2025)
  • Table 249. MEA Digital Medicines, by Application USD Million (2020-2025)
  • Table 250. MEA Digital Medicines, by Components USD Million (2020-2025)
  • Table 251. MEA Digital Medicines, by End User USD Million (2020-2025)
  • Table 252. Middle East Digital Medicines, by Type USD Million (2020-2025)
  • Table 253. Middle East Digital Medicines, by Application USD Million (2020-2025)
  • Table 254. Middle East Digital Medicines, by Components USD Million (2020-2025)
  • Table 255. Middle East Digital Medicines, by End User USD Million (2020-2025)
  • Table 256. Africa Digital Medicines, by Type USD Million (2020-2025)
  • Table 257. Africa Digital Medicines, by Application USD Million (2020-2025)
  • Table 258. Africa Digital Medicines, by Components USD Million (2020-2025)
  • Table 259. Africa Digital Medicines, by End User USD Million (2020-2025)
  • Table 260. North America Digital Medicines, by Country USD Million (2020-2025)
  • Table 261. North America Digital Medicines, by Type USD Million (2020-2025)
  • Table 262. North America Digital Medicines, by Application USD Million (2020-2025)
  • Table 263. North America Digital Medicines, by Components USD Million (2020-2025)
  • Table 264. North America Digital Medicines, by End User USD Million (2020-2025)
  • Table 265. United States Digital Medicines, by Type USD Million (2020-2025)
  • Table 266. United States Digital Medicines, by Application USD Million (2020-2025)
  • Table 267. United States Digital Medicines, by Components USD Million (2020-2025)
  • Table 268. United States Digital Medicines, by End User USD Million (2020-2025)
  • Table 269. Canada Digital Medicines, by Type USD Million (2020-2025)
  • Table 270. Canada Digital Medicines, by Application USD Million (2020-2025)
  • Table 271. Canada Digital Medicines, by Components USD Million (2020-2025)
  • Table 272. Canada Digital Medicines, by End User USD Million (2020-2025)
  • Table 273. Mexico Digital Medicines, by Type USD Million (2020-2025)
  • Table 274. Mexico Digital Medicines, by Application USD Million (2020-2025)
  • Table 275. Mexico Digital Medicines, by Components USD Million (2020-2025)
  • Table 276. Mexico Digital Medicines, by End User USD Million (2020-2025)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Digital Medicines: by Type USD Million (2014-2019)
  • Figure 5. Global Digital Medicines: by Application USD Million (2014-2019)
  • Figure 6. Global Digital Medicines: by Components USD Million (2014-2019)
  • Figure 7. Global Digital Medicines: by End User USD Million (2014-2019)
  • Figure 8. South America Digital Medicines Share (%), by Country
  • Figure 9. Asia Pacific Digital Medicines Share (%), by Country
  • Figure 10. Europe Digital Medicines Share (%), by Country
  • Figure 11. MEA Digital Medicines Share (%), by Country
  • Figure 12. North America Digital Medicines Share (%), by Country
  • Figure 13. Global Digital Medicines share by Players 2019 (%)
  • Figure 14. Global Digital Medicines share by Players (Top 3) 2019(%)
  • Figure 15. Global Digital Medicines share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. 2Morrow (United States) Revenue, Net Income and Gross profit
  • Figure 18. 2Morrow (United States) Revenue: by Geography 2019
  • Figure 19. Livongo Health (United States) Revenue, Net Income and Gross profit
  • Figure 20. Livongo Health (United States) Revenue: by Geography 2019
  • Figure 21. WellDoc (United States) Revenue, Net Income and Gross profit
  • Figure 22. WellDoc (United States) Revenue: by Geography 2019
  • Figure 23. Wellthy Therapeutics (India) Revenue, Net Income and Gross profit
  • Figure 24. Wellthy Therapeutics (India) Revenue: by Geography 2019
  • Figure 25. Ayogo Health (Canada) Revenue, Net Income and Gross profit
  • Figure 26. Ayogo Health (Canada) Revenue: by Geography 2019
  • Figure 27. Proteus Digital Health (United States) Revenue, Net Income and Gross profit
  • Figure 28. Proteus Digital Health (United States) Revenue: by Geography 2019
  • Figure 29. Omada Health (United States) Revenue, Net Income and Gross profit
  • Figure 30. Omada Health (United States) Revenue: by Geography 2019
  • Figure 31. Noom (United States) Revenue, Net Income and Gross profit
  • Figure 32. Noom (United States) Revenue: by Geography 2019
  • Figure 33. Pear Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pear Therapeutics (United States) Revenue: by Geography 2019
  • Figure 35. Propeller Health (United States) Revenue, Net Income and Gross profit
  • Figure 36. Propeller Health (United States) Revenue: by Geography 2019
  • Figure 37. Global Digital Medicines: by Type USD Million (2020-2025)
  • Figure 38. Global Digital Medicines: by Application USD Million (2020-2025)
  • Figure 39. Global Digital Medicines: by Components USD Million (2020-2025)
  • Figure 40. Global Digital Medicines: by End User USD Million (2020-2025)
  • Figure 41. South America Digital Medicines Share (%), by Country
  • Figure 42. Asia Pacific Digital Medicines Share (%), by Country
  • Figure 43. Europe Digital Medicines Share (%), by Country
  • Figure 44. MEA Digital Medicines Share (%), by Country
  • Figure 45. North America Digital Medicines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • 2Morrow (United States)
  • Livongo Health (United States)
  • WellDoc (United States)
  • Wellthy Therapeutics (India)
  • Ayogo Health (Canada)
  • Proteus Digital Health (United States)
  • Omada Health (United States)
  • Noom (United States)
  • Pear Therapeutics (United States)
  • Propeller Health (United States)
Additional players considered in the study are as follows:
Akili Interactive Labs , Voluntis , AliveCor
Select User Access Type

Key Highlights of Report


Mar 2020 224 Pages 56 Tables Base Year: 2020 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Digital Medicines Market Quantitative research analysis
Global Digital Medicines Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Digital Medicines Market Report?

Have a Query? Click Here

Other Related Reports

Sevoflurane Source Comprehensive Study by Type (Human Series, Animal Series), Application (Hospitals, Other Medical Institutions) Players and Region - Global Market Outlook to 2028
$ 3500
Polymer-Based Drug Delivery Comprehensive Study by Type (Natural polymers (such as cellulose, starch), Semi-synthetic polymers (such as cellulose derivatives), Synthetic polymers (such as polyethene,...
$ 3750
Diabetes Care Drugs Comprehensive Study by Type (Oral Anti-diabetic drugs, Insulin, Non-insulin Injectable drugs, Combination Drugs), Application (Adults, Younger), Distribution Channel (Online, Offl...
$ 3350
Coronavirus Vaccine Comprehensive Study by Application (Hospitals, Research Laboratories, Clinics), End-users (Adults, Children) Players and Region - Global Market Outlook to 2028
$ 3500
Fluvastatin Sodium Drug Comprehensive Study by Type (Tablets, Capsules), Application (Cardiovascular Disease, Plasma Cholesterol Levels), Distribution Channel (Online, Offline), End-User (Hospital Ph...
$ 3350
Hydroxychloroquine Comprehensive Study by Type (Hydroxychloroquine 200 mg, Hydroxychloroquine 300 mg, Hydroxychloroquine 400 mg), Application (Lupus Erythematosus, Rheumatoid Arthritis, COVID-19, Oth...
$ 3650